Lily is the CEO of Fosun Pharma USA, who is responsible for Commercial Operations, BD and Investment Activities in the US.

​

Lily has extensive experience in BD/Investment, Strategy and Operations. Prior to Fosun pharma USA, her experiences include management consultant at Bain & Co., BD/M&A, Strategic planning and R&D Management at Novartis/Sandoz, Wyeth, Millennium, Coley and ArQule. Lily has led the negotiation and execution of over 40 product BD/investment deals, including innovative and generic products.

​

Lily received a B.S. from Peking University, PhD in Molecular Biology from Cornell University and an MBA from MIT.